Elewa Mohamed, Mitra Sandip, Jayanti Anuradha
Consultant Nephrologist, Manchester University NHS Foundation Trust, Manchester, UK.
Consultant Nephrologist, Manchester University NHS Foundation Trust, Honorary Professor of Medicine, University of Manchester, Manchester, UK.
Clin Kidney J. 2023 Jan 30;16(7):1092-1101. doi: 10.1093/ckj/sfad020. eCollection 2023 Jul.
With the increasing prevalence of chronic kidney disease, the number of people receiving renal replacement is expected to increase by 50% by 2030. Cardiovascular mortality remains significantly higher in this population. The presence of valvular heart disease (VHD) in patients with end-stage renal disease is associated with poor survival. In a dialysis cohort, we assessed the prevalence and characteristics of patients with significant VHD, the association with clinical parameters and the impact on survival.
Echocardiographic parameters for dialysis recipients from a single centre in the UK were collected. Significant left-sided heart disease (LSHD) was defined as moderate or severe left valvular lesions or left ventricular systolic dysfunction (LVSD) (ejection fraction <45%) or both. Baseline demographic and clinical characteristics were ascertained.
In 521 dialysis recipients {median age 61 years [interquartile range (IQR) 50-72], 59% male}, 88% were on haemodialysis and the median dialysis vintage was 2.8 years (IQR 1.6-4.6). A total of 238 (46%) had evidence of LSHD: 102 had VHD, 63 had LVSD and 73 had both. Overall, 34% had evidence of left-sided VHD. In multivariable regression analysis, age and use of cinacalcet were associated with higher odds of VHD {odds ratio [OR] 1.03 [95% confidence interval (CI) 1.02-1.05] and OR 1.85 [95% CI 1.06-3.23], respectively}, while the use of phosphate binders was associated with increased odds of aortic stenosis [AS; OR 2.64 (95% CI 1.26-5.79)]. The 1-year survival was lower in VHD [78% versus 86% (95% CI 0.72-0.84 and 0.83-0.90), respectively] and in LSHD [78% versus 88% (95% CI 0.73-0.83 and 0.85-0.92), respectively]. In AS, the 1-year survival was 64% (95% CI 0.49-0.82). Using propensity score matching to adjust for age, diabetes and low serum albumin, AS was significantly associated with lower survival ( = .01). LSHD was significantly associated with worse survival ( = .008) compared with survival in LVSD ( = .054).
A high proportion of dialysis patients have clinically significant LSHD. This was associated with higher mortality. In valvular heart disease, the development of AS is independently associated with higher mortality in dialysis patients.
随着慢性肾脏病患病率的不断上升,预计到2030年接受肾脏替代治疗的人数将增加50%。该人群的心血管死亡率仍然显著更高。终末期肾病患者中瓣膜性心脏病(VHD)的存在与生存率低相关。在一个透析队列中,我们评估了重度VHD患者的患病率和特征、与临床参数的关联以及对生存的影响。
收集了来自英国一个中心的透析患者的超声心动图参数。重度左侧心脏病(LSHD)定义为中度或重度左侧瓣膜病变或左心室收缩功能障碍(LVSD)(射血分数<45%)或两者兼有。确定了基线人口统计学和临床特征。
在521名透析患者中(中位年龄61岁[四分位间距(IQR)50 - 72],59%为男性),88%接受血液透析,中位透析时间为2.8年(IQR 1.6 - 4.6)。共有238名(46%)有LSHD证据:102名有VHD,63名有LVSD,73名两者兼有。总体而言,34%有左侧VHD证据。在多变量回归分析中,年龄和西那卡塞的使用与VHD的较高几率相关(优势比[OR]分别为1.03[95%置信区间(CI)1.02 - 1.05]和OR 1.85[95% CI 1.06 - 3.23]),而使用磷结合剂与主动脉瓣狭窄[AS]几率增加相关[OR 2.64(95% CI 1.26 - 5.79)]。VHD患者的1年生存率较低[分别为78%对86%(95% CI 0.72 - 0.84和0.83 - 0.90)],LSHD患者也是如此[分别为78%对88%(95% CI 0.73 - 0.83和0.85 - 0.92)]。在AS患者中,1年生存率为64%(95% CI 0.49 - 0.82)。使用倾向评分匹配来调整年龄、糖尿病和低血清白蛋白后,AS与较低生存率显著相关(P = 0.01)。与LVSD患者的生存率相比,LSHD与较差生存率显著相关(P = 0.008)(P = 0.054)。
高比例的透析患者有临床上显著的LSHD。这与较高死亡率相关。在瓣膜性心脏病中,AS的发生与透析患者的较高死亡率独立相关。